An observational study in Sepsis, sponsored by Mayo Clinic. Active, not recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-24.
Sponsored by Mayo Clinic · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 16 studies in Sepsis by Mayo Clinic — 2 open to participants now, 4 under way, none of them phase 3. Sepsis · Mayo Clinic.
Among the 16 studies in Sepsis by Mayo Clinic, this one is one of 2 that started in 2025, is one of 6 observational ones, and was the 14th registered.
2,425 studies on the registry are indexed under Sepsis; 543 are open to participants now.
Browse Sepsis studies →2 of the 16 studies in Sepsis by Mayo Clinic are open now, in 1 country. Recruiting first, the newest first:
Mayo Clinic · Sites in United States
Ages 18+
Mayo Clinic · Sites in United States
Ages 18+
By country, each count listing its studies:
Of the 319 Sepsis studies recruiting now, 212 (66%) set no upper age limit and 52 (16%) stop at 75 or younger; 67 take children under 18; 43 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
16 studies; the count open now beside each. This study's row is marked.
First in 2003; this study’s year is marked. 2 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 1,000 is above the median of 150 across 1,166 observational studies indexed under Sepsis.
Median enrollment 354 across the 10 interventional studies, 258 across the 6 observational. Of the 12 that completed or were terminated, 1 (8%) have results posted.
This tab as a report to print or save as PDF → With an account.
Mayo Clinic is the lead sponsor of 3,272 studies on the registry; 672 are open to participants now.
Of its 452 completed or terminated interventional studies of FDA-regulated products, 322 (71%) have results posted.
3 of the studies in Sepsis by Mayo Clinic that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06817408Mayo ClinicDynamics of Organ Damage and Immune Exhaustion During Sepsis | 2026-12 |
| NCT06905080Mayo ClinicDialysis Catheter Caps Case Feasibility Study | 2026-12-31 |
| NCT07287332Mayo ClinicBLOOM: Pragmatic Feasibility Trial | 2027-03 |
Add all 3 to your calendar (.ics) → With an account.
Among the 16 studies in Sepsis by Mayo Clinic, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is a prospective, non-randomized study investigating if organ damage and immune changes can be measured by liquid biopsy NGS through advanced analytical methods.
To determine the sample size needed to derive a signature matrix to identify novel biomarkers in sepsis, investigators performed a mathematical modeling exercise of the lower limits of sensitivity of this liquid biopsy approach. The detection limit of cell-free nucleic acid analysis is determined in part by the number of independent transcripts or "reporters" that are interrogated. Using an established and independently validated binomial model that was previously applied to the prediction of circulating tumor nucleic acid detection limits, investigators estimated the probability of cell-free nucleic acid detection in sepsis patients based on the number of unique tissue-specific reporters (i.e., hepatic transcripts that may reflect disease severity). This yields a result of n=18 per group to achieve 0.90 power at alpha=0.05. The investigators will thus plan to analyze data from n=18 per cell/tissue type to derive the signature matrix for this project.
Patients who've developed a shocked state or clinical concern that are going thru the Emergency Department.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
One additional blood draw in the Emergency Department as part of their standard of care visit.
Patient Survival
Overall survival
Time frame: From date of patient enrollment until date of death for any cause or up to 1 year after patient enrollment date, whichever comes first.
ICU Time
Time for patient in ICU
Time frame: Up to 1 year after patient enrollment date
Hospital Stay Duration
Days
Time frame: Up to 1 year after patient enrollment date
Renal Replacement Therapy
If patient needed renal replacement therapy during duration on study.
Time frame: Up to 1 year after patient enrollment date
Ventilator and Vasopressor Free Days
Time frame: Up to 1 year after patient enrollment date
Plan to share: No
Started Mar 2025 (actual). Primary completion is estimated for Dec 2026, 21 months after the start.
Of 496 non-industry observational studies under Sepsis, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 57. This study's planned 21 months is below that.
Counting every sponsor, half of 548 studies reached it within 27 months; a quarter within 12 and three quarters within 55.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.